WMT raises €3.7M Series A round
14 October 2025· Heidelberg, Germany· health, oncology, biotech, b2b, deep_hardware
The funds will be used to advance the company's 'Translational Trap' platform and move initial drug programs for autoimmune disorders and viral infections toward clinical development.
Investors
LeadMarathon Beteiligungs AG
Also participating
L-BankCarma Fund
About WMT
Stage
Series A
Headquarters
Heidelberg, Germany
Founded
2020
Team Size
6–20
Sectors
healthoncologybiotechb2bdeep_hardware